In inflammatory diseases, circulating neutrophils are recruited to sites of injury. Attractant signals are provided by many different chemotactic molecules, such that blockade of one may not prevent neutrophil recruitment effectively. The Slit family of secreted proteins and their transmembrane receptor, Robo, repel axonal migration during CNS development. Emerging evidence shows that by inhibiting the activation of Rho-family GTPases, Slit2/Robo also inhibit migration of other cell types toward a variety of chemotactic factors in vitro and in vivo. The role of Slit2 in inflammation, however, has been largely unexplored. We isolated primary neutrophils from human peripheral blood and mouse bone marrow and detected Robo-1 expression. Using videomicroscopic live cell tracking, we found that Slit2 selectively impaired directional migration but not random movement of neutrophils toward fMLP. Slit2 also inhibited neutrophil migration toward other chemoattractants, namely C5a and IL-8. Slit2 inhibited neutrophil chemotaxis by preventing chemoattractant-induced actin barbed end formation and cell polarization. Slit2 mediated these effects by suppressing inducible acti-vation of Cdc42 and Rac2 but did not impair activation of other major kinase pathways involved in neutrophil migration. We further tested the effects of Slit2 in vivo using mouse models of peritoneal inflammation induced by sodium periodate, C5a, and MIP-2. In all instances, Slit2 reduced neutrophil recruitment effectively (PϽ0.01). Collectively, these data demonstrate that Slit2 potently inhibits chemotaxis but not random motion of circulating neutrophils and point to Slit2 as a potential new therapeutic for preventing localized inflammation.
Introduction
Neutrophils are a critical component of the innate immune system and provide the first line of defense against bacterial and fungal pathogens. During an inflammatory response, neutrophils are recruited to sites of inflammation in a series of coordinated interactions with vascular endothelial cells. Traffic signals are provided by diverse chemoattractant molecules, including chemokines such as IL-8 and bacterial products such as formylated peptides. These chemoattractants recruit circulating neutrophils to sites of inflammation and activate recruited neutrophils to adhere firmly to the endothelium. Although their potent antimicrobial arsenal makes neutrophils efficient at fighting microorganisms, it is also capable of causing injury to the surrounding tissue. Indeed, neutrophils inflict significant tissue damage in inflammatory conditions, including ischemia-reperfusion injury of solid organs, acute respiratory distress syndrome, and rheumatoid arthritis [1] [2] [3] [4] . Once recruited to sites of injury, infiltrating neutrophils release reactive oxygen species and degradative enzymes, fueling local tissue destruction.
Anti-inflammatory drugs such as aspirin and glucocorticoids are widely used and yet, have shown modest success in reducing neutrophil-mediated injury. These drugs attenuate activation of transcription factors such as NF-B, thereby reducing expression of cytokines [5] . An alternative approach to prevent neutrophil-mediated tissue damage would be blockade of chemotactic pathways that recruit neutrophils to sites of inflammation. Indeed, some chemokine receptor antagonists or blocking antibodies have shown success in animal models and are undergoing clinical trials [6] . However, given the number of chemoattractant signals that recruit neutrophils, it is unlikely that targeting a single chemokine/chemokine receptor pathway would achieve widespread clinical success. Thus, localized general blockade of inflammatory chemoattractants could represent a clinically useful strategy to reduce neutrophil-mediated tissue damage.
Clues as to how generalized blockade of neutrophil chemoattractant signals might be realized are provided in the neurodevelopmental literature. The Slit family of secreted proteins, together with their transmembrane receptor Robo, repels migration of axons and neurons during development of the CNS. Slit is expressed along the midline of the developing CNS, and its interaction with Robo prevents axons from crossing the midline repeatedly and randomly [7, 8] . Although the importance of Slit/Robo interactions in development has been demonstrated, the intracellular signaling pathways that lead to Slit-mediated inhibition of migration remain unclear. Data from Drosophila suggest that Abelson kinase and Ena proteins associate with the intracellular domains of Robo-1 and may be involved in the repulsive response to Slit2 [9] . Addition of extracellular Slit2 to neuronal cells results in the recruitment of soluble srGAP1 to the cytoplasmic tail of Robo-1 [10] .
In addition to neuronal cells, Slit2 and Robo-1 inhibit migration of other cell types, including vascular smooth muscle cells, breast cancer cells, and brain tumor cells [11] [12] [13] . Several studies have demonstrated that Slit2 inhibits migration of hematopoietic cells, including murine macrophages, cultured cells of granulocytic lineage, dendritic cells, and primary human T lymphocytes, toward chemoattractant signals [14 -17] . Importantly, Slit2 not only inhibits cell migration toward one type of chemoattractant signal but also toward many diverse signals, including platelet-derived growth factor and the chemokines CXCL12 and CCL2 [12, 13, 16, 17] . In vivo, Slit2 inhibits neoangiogenesis by impairing pathologic migration of endothelial cells to vascular endothelial growth factor [18] . Existing data point to a role for Slit2 as a generalized "antimigration" signal, which inhibits cell migration universally. However, the potential use of Slit2 to prevent inflammation has been largely unexplored. In particular, there is a paucity of data addressing the effects of Slit2 on migration of human leukocytes, especially neutrophils. Moreover, the mechanisms by which Slit2 mediates its antimigratory effects are incompletely understood.
The aim of this study was to assess, in real-time, the effect of Slit2 on recruitment of primary neutrophils. We observed that primary human and murine neutrophils express the Slit2 receptor Robo-1 and that Slit2 inhibits directional migration but not random migration of neutrophils toward a chemotactic stimulus. Our studies demonstrate that Slit2 mediates these effects by preventing chemoattractant-induced cell polarization and generation of actin-free barbed ends, a prerequisite for directional migration of neutrophils. Our data suggest further that Slit2 prevents chemoattractant-induced free barbed-end formation by suppressing inducible activation of the small GTPases, Cdc42 and Rac2, but does not affect activation of other major kinase pathways involved in neutrophil migration. To investigate whether Slit2 prevents neutrophil chemotaxis in vivo, we used mouse models of peritoneal inflammation and observed a significant reduction in the number of neutrophils recruited to the peritoneum in response to diverse inflammatory stimuli in the presence of Slit2 [19] . Taken together, these data indicate a novel role for the axonal repellent Slit, as an anti-inflammatory agent that specifically prevents chemotactic trafficking of circulating neutrophils.
MATERIALS AND METHODS

Reagents and antibodies
Unless otherwise stated, reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). Polymorphprep neutrophil separation medium was purchased from Axis-Shield (Norway). The following primary antibodies were used: anti-Robo-1 (Abcam, Cambridge, MA, USA, and Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-myc 9E10 (Covance, Quebec, Canada), anti-human Cdc42 (Cell Signaling, Danvers, MA, USA), anti-human Rac2 (Upstate Biotechnology, Lake Placid, NY, USA), anti-mouse CD3 (BD Biosciences, Mississauga, Ontario, Canada), anti-B220 (BD Biosciences), anti-NK1.1 (BD Biosciences), anti-F4/80 (Serotec, Raleigh, NC, USA), and anti-Erk, anti-phospho-Erk, anti-p38 MAPK, anti-phospho-p38 MAPK, anti-Akt, and anti-phospho-Akt. Rhodamine-conjugated phalloidin was from Invitrogen Canada (Burlington, Ontario, Canada). The following secondary antibodies were used: Cy3-conjugated anti-rabbit IgG, Cy2-conjugated antihuman IgG, PE-conjugated anti-rat IgG and anti-mouse IgG (Jackson Immunoresearch Laboratories, Bar Harbor, ME, USA), and HRP-conjugated anti-rabbit IgG and anti-mouse IgG (Jackson Immunoresearch Laboratories). C5a was purchased from Biovision, Inc. (Mountain View, CA, USA), IL-8 from Invitrogen (Carlsbad, CA, USA), and MIP-2 from R&D Systems (Minneapolis, MN, USA).
Isolation of primary human and murine neutrophils
Human blood was obtained from healthy volunteers, and neutrophils were isolated using two methods. For experiments testing the activation of Rac and Cdc42, neutrophils were isolated by Dextran sedimentation as described with slight modifications [20] . Briefly, 2 vol blood was mixed with 1 vol 6% Dextran T-500 in 0.9% NaCl and set at room temperature until clear separation of layers was seen (ϳ30 min). The leukocyte-rich upper layer was collected and centrifuged at 260 g at room temperature for 5 min. The cell pellet was resuspended in a volume of 0.9% NaCl, equal to the starting volume of blood, laid onto 10 ml Ficoll-Hypaque solution, and centrifuged at 460 g for 30 min. RBCs were lysed by adding 20 ml ice-cold 0.2% NaCl for 30 s, resuspended in 20 ml ice-cold 1.6% NaCl, and centrifuged at 250 g at 4°C for 5 min. Neutrophils were resuspended in ice-cold PBS with 0.5% BSA. Cells were kept on ice for subsequent experimental use. The purity of neutrophils isolated in this manner was assessed by modified Wright-Giemsa stain (Hema-Tek stain pack, Bayer, Elkhart, IN, USA) using an automated stainer (Hema-Tek 2000, Bayer) and was consistently Ͼ95%. For all other experiments, the Polymorphprep gradient separation procedure was performed according to the manufacturer's recommendations. Purified neutrophils were suspended in PBS without calcium and kept at room temperature. Prior to use, the neutrophils were resuspended in HBSS with 1 mM CaCl 2 and 1 mM MgCl 2 . Experiments were performed within 1-2 h of isolation of neutrophils. Cell purity was consistently Ͼ85-90%. Cell viability was Ͼ98% by Trypan blue exclusion. For RT-PCR experiments, a QIAmp RNA blood mini kit (Qiagen, Ontario, Canada) was used to isolate total RNA from human leukocytes isolated from whole blood, according to the manufacturer's specifications.
Primary murine neutrophils were isolated as described previously [19, 21] . Briefly, adult CD1 mice were killed by CO 2 inhalation. Femurs and tibias were removed, and bone marrow was extracted. Bone marrow cells were layered onto discontinuous Percoll gradients of 81%/65%/55%. Mature neutrophils were isolated from the 81%/65% interface. More than 85% of cells were neutrophils, as assessed by Wright-Giemsa staining.
Slit2 expression and purification
A stable HEK293 cell line expressing full-length human Slit2 with a c-myc tag at its carboxyl terminus was a kind gift from Drs. Rolando del Maestro (McGill University, Montreal, Canada) and Yi Rao (Washington University, St. Louis, MO, USA) and grown as described [22] . Recombinant Slit2 was purified from the conditioned medium using two methods. Conditioned medium was concentrated and Slit2 purified by affinity chromatography using anti-c-myc antibody 9E10 (Covance) and the Size Primary immunoprecipitation kit (Thermo Scientific, Rockford, IL, USA), following the manufacturer's instructions. Slit2 was also obtained by Superdex-200 size exclusion chromatography. Briefly, conditioned medium was concentrated using Centricon Plus-20 (Millipore, Billerica, MA, USA) and loaded onto the column [16] , which was then washed with PBS, and fractions containing Slit2 were pooled, concentrated, aliquoted, and stored in -80°C before use. The presence of Slit2 was verifed using silver staining and immunoblotting with anti-myc antibody (Supplemental Fig. 1, A and B) . The above protocol was repeated with conditioned medium from control HEK293 cells to obtain control medium. This preparation of Slit2 was titrated and used at a concentration of 0.6 g/ml. In parallel assays, control medium was used in lieu of Slit2.
Large-scale preparation of Slit2 was performed by transfection of HEK293-EBNA1 cells. Briefly, human Slit2 cDNA (mammalian gene collection: 177513; aa 26-1529 of NP_004778) was amplified using forward (CTATCTAGACCTCAGGCGTGCCCGGCGCAGTGC) and reverse (CTAG-GATCCGGACACACACCTCGTACAGC) primers containing XbaI and BamHI restriction sites. The amplified cDNA was cloned into the pTT28 vector digested with NheI and BamHI. The pTT28 vector is a derivative of the pTT5 vector [23, 24] and contains a synthetic and codon-optimized signal peptide (MGELLLLLLLGLRLQLSLG) and a C-terminal (His) 8 G tag separated by NheI and BamHI restriction sites. HEK293-EBNA1 cells (clone 6E) were transfected with 1 g/ml cDNA as described previously [25] . Culture medium was harvested 120 h post-transfection, clarified by centrifugation (4000 g for 15 min), and filtered through a 0.45-m membrane. Slit2 secreted into the medium was purified by immobilized metal-affinity chromatography using a Fractogel-cobalt column equilibrated in PBS. Following washing steps with 5 CV Wash1 buffer (50 mM sodium phosphate, pH 7.0, and 300 mM NaCl), followed by 5 CV Wash2 buffer (50 mM sodium phosphate, pH 7.0, 300 mM NaCl, and 25 mM imidazole), bound Slit2 was eluted with elution buffer (50 mM sodium phosphate, pH 7.0, 300 mM NaCl, and 25 mM imidazole). The pooled, eluted material was desalted immediately on Econo-Pac™ 10 columns (Bio-Rad Laboratories, Mississauga, Ontario, Canada), equilibrated previously with PBS, according to the manufacturer's specifications. Protein concentration was determined by absorbance at 280 nm using a calculated Slit2 molar extinction coefficient of 114600 (http://ca.expasy.org/tools/protparam.html). For Western blots, proteins were resolved on reducing SDS-PAGE (4 -12% Nu-PAGE Bis-Tris gradient gel, Invitrogen), followed by transfer to a 0.2-mm Protran nitrocellulose membrane (Schleicher and Schuell, Keene, NH, USA) in Tris-glycine buffer for 1 h at 300 mA. Purity was verified by Ponceau staining and immunoblotting (Supplemental Fig. 1 , C and D). The membrane was incubated in blocking reagent (Roche Diagnostics, Laval, Canada) and then probed with anti-polyHis-HRP antibody (Sigma-Aldrich) for 1 h (Supplemental Fig. 1D ). Detection was performed using BM chemiluminescence blotting substrate (Roche Diagnostics) with a Kodak Digital Science Image Station 440cf equipped with Kodak Digital Science 1D image analysis software, version 3.0 (Eastman Kodak, New York, NY, USA).
Although Slit2 expression and purification were carried out using HEK293-EBNA1 cells, in theory, endotoxin could be present in the plasmid preparation used to transfect the cells and/or in the tubing, vessels, and buffers used during protein purification. We measured endotoxin levels in purified Slit2 stock preparations using ToxinSensor Chromogenic Limulus amoebocyte lysate endotoxin assay kit (GenScript Corp., Piscataway, NJ, USA). Endotoxin concentrations ranged from 0.2 ng/ml to 0.8 ng/ml, yielding final experimental concentrations of 12-40 pg/ml, which are well below those thought to activate leukocytes [26] . To verify this point, we added similar concentrations of endotoxin in neutrophil Transwell assays and found that such levels of endotoxin had no effect on neutrophil migration (Supplemental Fig. 2 ).
RT-PCR
RNA isolation and RT-PCR were performed using the QIAamp RNA blood mini kit and the Qiagen One-Step RT-PCR kit (Qiagen), as described [13] . The following primers specific for Robo-1, as described previously, were used: GGCCCCACTCCCCCTGTTCG (forward primer) and TCCTCTTCT-GGCGCATCCGTATCC (reverse primer) [13] . Amplified products were analyzed by electrophoresis on 2% agarose gels containing ethidium bromide to confirm primer specificity and PCR product size (278 bp).
Immunofluorescent labeling
Primary human and mouse neutrophils were allowed to settle onto fibronectin-coated coverslips and to adhere for 3 min at room temperature. The cells were fixed with 4% paraformaldehyde for 10 min at 4°C. Neutrophils were stained with rabbit anti-Robo-1 antibody (1 g/ml) for 2 h, washed, and then incubated with anti-rabbit-Cy3 secondary antibody for 1 h. In some experiments, human or mouse neutrophils were incubated with fMLP (1 M) for 3 min, following incubation with purified Slit2 (4.5 g/ml). Cells were fixed, permeabilized, and incubated with rhodamineconjugated phalloidin (1:500) for 30 min to visualize actin. A Leica DMIRE2 spinning disc confocal microscope (Leica Microsystems, Toronto, Ontario, Canada), equipped with a Hamamatsu back-thinned EM-CCD and Volocity™ software (Improvision, Lexington, MA, USA), was used to capture images.
Flow cytometry
Cell surface expression of Robo-1 was verified by incubating human and mouse neutrophils with anti-Robo-1 antibody, followed by PE-conjugated secondary antibody. Analysis was performed using a FACSCalibur flow cytometer (BD Biosciences) and FlowJo software (Tree Star, Inc., Ashland, OR, USA), as described previously [27, 28] .
Immunoblotting
Freshly isolated human or mouse neutrophils were pretreated with control medium or Slit2 for 10 min and then activated with fMLP (1 M). Cells were lysed using ice-cold 2ϫ lysis buffer. Samples were run on SDS-PAGE, transferred to 0.2 m PVDF (Millipore) membrane, and probed for Robo-1 or for phosphorylated and total Akt, Erk, and p38 MAPK. Immunoreactive bands were visualized by ECL (Amersham Biosciences, UK Ltd., Buckinghamshire, UK), recorded on X-ray film. Prior to performing experiments, a time-course study was performed to determine the optimal point at which to measure phosphorylation of Akt, Erk, and p38 MAPK following exposure to fMLP. Of samples harvested at 15-180 s, the maximum signal was observed at 30 s, and therefore, a 30-s time-point was used for all subsequent experiments.
Migration assay
Freshly isolated neutrophils (10 6 cells/100 l) were incubated with medium alone, FPLC-enriched Slit2 (0.6 g/ml), control medium, or purified Slit2 at the indicated concentrations for 10 min. Cells were loaded into the top chamber of a 3-m Transwell insert (Corning Life Sciences, Corning, NY, USA) in a 24-well plate. A coverslip was added to the bottom chamber, which was filled with 600 l HBSS alone, fMLP (1 M), C5a (2 g/ml), or IL-8 (0.13 g/ml) [29 -32] . Into the bottom chamber, Slit2, control medium, or HBSS was dispensed. Transwell plates were incubated for 1 h at 37°C. To determine the number of neutrophils that had migrated from the top to the bottom chamber, the filter was removed, and neutrophils in the lower chamber were spun down rapidly onto the coverslips, fixed with 4% paraformaldehyde, washed, and labeled with DAPI. A Leica DMIRE microscope was used to take representative 40ϫ and 63ϫ high-power images. A Nikon light microscope was used to count at least 10 random fields from each coverslip. The data represent the mean value Ϯ sem from at least four independent experiments for each treatment condition.
Micropipette chemotaxis assays
To measure neutrophil migration, round glass coverslips (25 mm diameter; Thomas Scientific, Swedesboro, NJ, USA), coated with fibronectin, were mounted in Leiden chambers, overlaid with 0.5 ml of the indicated solution, and placed on the heated stage of a Leica DM IRB microscope (Leica Microsystems). Next, a 100-l aliquot of the neutrophil suspension containing 10 6 cells was added, and cells were allowed to settle for 10 min. To induce chemotaxis, a point source of chemoattractant was delivered using a glass micropipette [33] [34] [35] [36] , and micropipettes were prepared from borosilicate capillaries with an outer diameter of 1.0 mm and an inner diameter of 0.78 mm (Sutter, Novato, CA, USA) using a model P-97 micropipette puller (Sutter). The tips of the micropipettes were 1.0 m in diameter. Precise positioning of the micropipette in the visual field was accomplished using a model 5171 micromanipulator (Eppendorf, Hamburg, Germany). Although the distance between the pipette and the individual cells adherent to the coverslip varied, the initial average distance of the cells under observation (i.e., those in the microscopic field under observation) ranged between 40 and 50 m. The pipette remained stationary, and diffusion of the chemoattractant generated a standing gradient [33] [34] [35] [36] . Images were acquired every 10 s until completion of the experiment. Only cells that started and remained in the field of view over the entire course of videocapture were analyzed. Using Volocity TM software (Improvision), the distance traveled was measured by tracking the centroid of each cell over time. Four different measures of chemotactic activity were assessed: total migration (distance), net migration (displacement), speed (distance/time), and directionality (displacement/distance). Total migration was defined as the sum of the absolute distances traveled in all of the individual time intervals. The net migration was calculated as the difference between the initial distance of the cell with respect to the pipette and that at the end of the experiment. Migration speed was calculated by dividing the total distance traveled by the elapsed time. Directionality was measured by obtaining a ratio of displacement over distance.
Actin-free barbed-end assay
To assess the effects of Slit2 on fMLP-induced actin polymerization, actin nucleation activity was measured as enhancement of pyrene actin fluorescence as described previously [21, 37, 38] . Briefly, human neutrophils (5ϫ10 6 /ml) were permeabilized for 10 s using 0.1 vol OG buffer or NP-40 (final concentration of 1%). Permeabilization was stopped by diluting the detergent with 3 vol buffer B. We then assayed for nuclei by adding pyrene-labeled rabbit skeletal muscle actin to a final concentration of 1 M and followed the fluorescence increase with a microplate reader (FLUOstaroptima, BMG Labtech, Nepean, Ontario, Canada) at excitation and emission wavelengths of 366 and 386 nm, respectively [21, 37] .
Cdc42 and Rac2 activation assays
Prior to performing these experiments, a time-course study was performed to determine the optimal point at which to measure activation of Rac2 and Cdc42 following exposure to fMLP. Of samples harvested at 15-180 s, the maximum signal was observed at 30 s, and therefore, a 30-s time-point was used for subsequent experiments. To assess the effects of Slit2 on fMLP-induced activation of Cdc42 and Rac2, pull-down assays were performed as described previously with slight modifications [39] . The PBD (aa 67-150) of PAK1 in the pGEX-4T3 vector was expressed as a GST fusion protein in BL21 (DE3) Escherichia coli cells. The GST-PBD fusion protein was affinitypurified using glutathione sepharose 4B beads (GE Healthcare Bio-Sciences, Piscataway, NJ, USA). Protein-bound beads were aliquoted and stored at -80°C for later use. Human neutrophils purified by dextran sedimentation (ϳ1ϫ10 7 /sample) were diluted in 0.5 ml 37°C warmed HEPES-HBSS and incubated with purified Slit2 (0.6 g/ml) at 37°C for 10 min. Cells were stimulated with fMLP (1 M) for 30 s at 37°C, and the reaction was stopped by adding 0.5 ml ice-cold 2ϫ lysis buffer. Samples were centrifuged at maximal speed in a bench-top centrifuge for 5 min at 4°C, and an aliquot of supernatant was used as loading control. The remaining supernatants were added to GST-PBD glutathione beads (20 g GST-PBD/sample). Samples were rotated at 4°C for 1 h and washed three times with cold wash buffer (50 mM Tris, pH 7.5, 40 mM NaCl, 0.5% NP-40, 30 mM MgCl 2 , 1 mM DTT, 1 mM PMSF, 0.1 mM NaVO 3 ), and 20 l 2ϫ Laemmli loading buffer was added. Samples were run on SDS-PAGE and transferred onto a 0.2-m PVDF (Millipore) membrane. Cdc42 and Rac2 were detected using anti-human Cdc42 and anti-human Rac2 primary antibodies and HRP-conjugated secondary antibody. Densitometry analysis was performed on the blots using Image J software.
To examine the effects of Slit2 on spatial distribution of activated Rac and Cdc42, assays were performed as described previously [33] . Briefly, mouse bone marrow-derived neutrophils were isolated, and 1 ϫ 10 6 cells were suspended in Nucleofector™ solution supplemented with 6 g cDNA expression plasmids encoding each of the YFP-tagged PBD of PAK (PAK-PBD-YFP), which selectively detects activated Rac and Cdc42, together with RFP-tagged H-Ras (H-Ras-RFP) to label the plasma membrane [21, 33] . Cells were transfected using a Cell Line V Nucleofector TM kit (Amaxa Biosystems, Amaxa, Inc., Gaithersburg, MD, USA) and the Nucleofector TM program Y-001 [21, 33] . Transfected cells were recovered carefully and transferred to IMDM, prewarmed to 37°C, and allowed to recover for 2 h. Approximately 20% of neutrophils were found to express PAK-PBD-YFP and H-Ras-RFP (data not shown). Neutrophils were placed on coverslips coated with 1% BSA, mounted in an Attafluor cell chamber (Invitrogen), and exposed to a point source of fMLP (1 M), dispensed through a glass micropipette [21, 33] . In some experiments, neutrophils were preincubated with purified Slit2 (4.5 g/ml) for 10 min. Cells were maintained on a microscope stage heated to 37°C, and digital images were acquired every 3-5 s using a Leica DMIRE2 inverted fluorescence microscope equipped with a Hamamatsu back-thinned EM-CCD camera and spinning disc confocal scan head [21, 33] . Images were acquired and analyzed using Volocity TM software. Following chemotactic stimulation with fMLP, the ratio of the fluorescence intensity of PAK-PBD-YFP:H-Ras-RFP was compared at the leading edge of the cell and the trailing edge of the cell [21, 33] . The normalized MFI was calculated for 19 cells from three independent experiments [33] .
Mouse peritonitis experiments
To determine the effects of Slit2 on neutrophil chemotaxis in vivo, we used a mouse model of sodium periodate-induced peritonitis as described previously [19] . All procedures were carried out in accordance with the Guide for the Humane Use and Care of Laboratory Animals and were approved by The Hospital for Sick Children Research Institute Animal Care Committee. Adult CD1 mice were injected i.p. with Slit2 (100 ng) or control medium and then 1 h later, with 1 ml 5 mM sodium periodate in PBS [15] . After 3 h, mice were killed, and the peritoneal exudate was collected by lavage with chilled PBS (5 ml/mouse). Infiltrating neutrophils were counted using an electronic cell counter (Becton Dickinson, San Jose, CA, USA), and neutrophil influx was confirmed by analyzing cytospun slides.
To determine whether Slit2 administered systemically prevents neutrophil recruitment, purified Slit2 (1.8 g in 0.2 ml normal saline) was administered by i.v. tail-vein injection. One hour later, 1 ml PBS containing sodium periodate (5 mM), C5a (10 g), or MIP-2 (2.5 g) was injected i.p. [40, 41] . After 3 h, mice were killed, peritoneal exudate collected, and infiltrating neutrophils counted as described above. The number of infiltrating monocytes/macrophages, T lymphocytes, B lymphocytes, and NK cells was determined by labeling cells with antibody directed to F4/80 (10 g/ml), CD3 (5 g/ml), B220 (2 g/ml), or NK1.1 (2 g/ml), respectively, and performing flow cytometry as described previously [27, 28] .
Statistical analysis
ANOVA, followed by Bonferonni post-hoc testing, was performed using SPSS statistical software to analyze the data from Transwell experiments. In all other cases, the Student's t-test was used. P Ͻ 0.05 was considered significant.
RESULTS
Primary human and mouse neutrophils express the Slit2 receptor, Robo-1
Robo-1 mRNA and protein expression were detected in human and mouse neutrophils (Fig. 1, A and B) [19, 21] . As Robo-1 expression has been demonstrated previously in primary human lymphocytes, as a positive control, we verified Robo-1 expression in human leukocytes isolated from whole blood ( Fig. 1A ) [16] . We detected two distinct bands for Robo-1 protein in mouse neutrophils, consistent with the splice variants reported previously (Fig. 1B) [42] . Using immunofluorescence microscopy and flow cytometry, we detected Robo-1 expression on the surface of human and murine neutrophils ( Fig. 1, C 
Slit2 inhibits migration of human neutrophils toward fMLP
We studied the effects of Slit2 on Transwell migration of human neutrophils. As expected, basal migration was minimal (Fig. 2, A and E) but increased in the presence of a fMLP chemotactic gradient (Fig. 2, B and E; PϽ0.001) . When no chemotactic gradient was present, purified Slit2 did not stimulate neutrophil transmigration (Fig. 2D ). However, Slit2 prevented neutrophil migration toward fMLP (1 M) in the lower chamber in a dose-dependent manner (compare Fig. 2, B and C; Fig. 2E, PϽ0 .001 for the two highest Slit2 concentrations tested). When a different preparation, namely, FPLC-enriched Slit2 from conditioned medium of Slit2-expressing HEK293 T cells, was tested, similar results were obtained, and peak effects were observed at a Slit2 concentration of 0.6 g/ml (data not shown). In this instance, control medium from mock-transfected cells had no effect on neutrophil migration, verifying that the Slit2 preparation did not contain any factors that could affect neutrophil migration inadvertently (data not shown). In the presence of a lower concentration of fMLP (0.1 M), 88 Ϯ 17 neutrophils/high power field were counted in the lower chamber. When Slit2 was also present, significantly fewer neutrophils migrated into the lower chamber (38Ϯ9; PϽ0.05). Together, these data demonstrate that Slit2 inhibits fMLP-induced migration of primary human neutrophils in a dose-dependent manner.
Slit2 inhibits migration of human neutrophils toward other chemoattractants
To determine whether Slit2 inhibits neutrophil migration toward different chemoattractant signals, we performed Transwell assays, in which C5a or IL-8 was placed in the lower chamber. Slit2 resulted in a fourfold and sixfold decrease in neutrophil migration toward IL-8 and C5a, respectively ( Fig. 2F ; IL-8: 93Ϯ23 cells/field; IL-8ϩSlit2: 23Ϯ5 cells/field; C5a: 51Ϯ10 cells/field; C5aϩSlit2: 8Ϯ3 cells/field; PϽ0.001 for C5a and IL-8). These data demonstrate that Slit2 is a potent inhibitor of neutrophil migration toward diverse types of chemotactic cues.
Slit2 inhibits directional but not random migration of human neutrophils
We next determined whether the observed effects of Slit2 on neutrophil migration were a result of inhibition of cell chemotaxis or chemokinesis, which is defined as random movement in response to a stimulant. Unlike chemokinesis, chemotaxis includes a vectoral assessment of migration and is defined as directional migration in response to a chemotactic gradient. Therefore, defects in chemokinesis result in the failure of a cell to move, and defects in chemotaxis result in the failure of a cell to move in the right direction.
In the absence of Slit2, neutrophils migrated efficiently toward a point source of fMLP (Supplemental Video 1 and Supplemental Fig. 3, A-C) . In the presence of Slit2, neutrophils moved randomly but failed to move toward the micropipette (Supplemental Video 2 and Supplemental Fig. 3 , D-F). These data suggest that Slit2 does not inhibit generalized movement of neutrophils but rather, their directionality.
To refine the analysis, we tracked the centroid of each neutrophil over time. Figure 3A depicts the migratory tracks of neutrophils exposed to a fMLP gradient, and Figure 3B represents the migratory tracks of neutrophils exposed to fMLP in the presence of Slit2. The displacement, speed, and directionality were determined for each cell. A neutrophil migrating efficiently (directly) up a chemotactic gradient would have similar displacement and distance measurements. As such, its directionality value would be close to 1. Conversely, a neutrophil moving randomly would have a smaller net displacement, despite traveling the same distance, thereby having a directionality value closer to 0. In the absence of fMLP, the average migration speed was 1.4 Ϯ 0.2 m/min (Fig. 3C ). Neutrophils incubated with fMLP alone had an average speed of 6.8 Ϯ 0.6 m/min ( Fig. 3C; PϽ0 .01 vs. no fMLP), no different from those incubated with fMLP together with Slit2 (6.5Ϯ0.6 m/ min; Fig. 3C ). In the absence of fMLP, the directionality ratio was 0.19 Ϯ 0.03, which increased to 0.61 Ϯ 0.04 when fMLP was present ( Fig. 3D; PϽ0.002 ). In the presence of Slit2, the directionality ratio was reduced significantly (Fig. 3D ; fMLPϩSlit2: 0.13Ϯ0.04; PϽ0.002 vs. fMLP). Taken together, these data demonstrate that Slit2 does not inhibit the random movement and speed of neutrophil migration but rather, prevents directional migration toward a chemotactic gradient. (E) Transwell assays were performed as described above in the presence of the indicated concentrations of Slit2. Random fields were counted using a Nikon light microscope. Mean number of cells counted per 63ϫ field Ϯ sem. *, P Ͻ 0.001; n ϭ 10. (F) Transwell migration assays were performed as described above. C5a (2 g/ml) or IL-8 (0.13 g/ml) was placed in the lower chamber in the presence or absence of purified Slit2 (4.5 g/ml). *, P Ͻ 0.001; n ϭ 4.
Slit2 inhibits chemoattractant-stimulated actin free barbed end formation in human neutrophils
We assayed the effects of Slit2 directly on actin free barbed end formation, an event critical for formation of protruding lamellipodia and neutrophil migration [21, 37, [43] [44] [45] [46] . In pyrene-actin polymerization curves generated, the slope is proportional to the free barbed end numbers [21, 37] . As expected, unstimulated neutrophils demonstrated low basal levels of free barbed-end generation, but fMLP promoted a rapid, sixfold increase (Fig. 4, A and B; PϽ0.04) . Similarly, when neutrophils were treated with control medium prior to stimulation with fMLP, we observed a fivefold increase in the rate of actin polymerization as compared with unstimulated cells (Fig. 4, A and B; PϽ0.01 ). In the presence of Slit2, fMLPinduced actin polymerization was considerably more modest, resulting in less than a threefold increase compared with unstimulated cells (Fig. 4, A and B; PϽ0.04 ). Slit2 reduced fMLPstimulated generation of actin filaments significantly (Fig. 4, A  and B ; PϽ0.05 vs. control medium). Accordingly, Slit2 inhibited accumulation of actin at the leading edge of neutrophils following exposure to fMLP (Fig. 4C) . Collectively, these data suggest that Slit2 inhibits directional migration of neutrophils by disrupting generation of high-affinity free barbed ends that drive actin filament elongation. This in turn inhibits actin assembly at the leading edge of migrating cells, thus preventing efficient chemotaxis.
Slit2 inhibits chemoattractant-induced polarization and activation of Rac2 and Cdc42 in primary human neutrophils
Following chemotactic stimulation, activation of the Rho GTPases, Rac and Cdc42, plays a key role in the reorganization of actin filaments [19, 21, 34] . As the predominant isoform of Rac in human neutrophils is Rac2, not Rac1, we studied activation of Rac2 specifically [47, 48] . We used GST beads conjugated to the PBD of PAK (PAK-PBD) to detect the activated, GTP-bound species of Rac and Cdc42 [39] . Unstimulated neutrophils had low basal levels of activated Rac2 and Cdc42 (Fig. 5, A and B) . Exposure to fMLP increased levels of activated Cdc42 by fivefold and of activated Rac2 by threefold (Fig. 5, A and B ; PՅ0.01 vs. unstimulated for Cdc42 and Rac2). Slit2 did not affect basal levels of activated Rac2 and Cdc42 but inhibited fMLP-induced activation of these GTPases significantly (Fig. 5, A and B; PϽ0.05 ). Upon stimulation with fMLP, levels of activated Cdc42 and Rac2 in the presence of Slit2 were less than half of those observed when Slit2 was not present (Fig. 5B; PϽ0.05) . Moreover, Slit2 prevented spatial accumulation of activated Rac and Cdc42 at the leading edge of fMLP-stimulated neutrophils (Fig. 5, C and D; PϽ0.001) .
These data demonstrate that Slit2 inhibits neutrophil chemotaxis and actin polymerization by preventing cell polarization and disrupting generation and recruitment to the lamellipodium of activated Rac2 and Cdc42. In some experiments, neutrophils were also exposed to anti-myc antibody affinity-purified Slit2 (0.6 g/ml). Volocity TM (Improvision) software was used to track the centroid of migrating neutrophils and thus, calculate the total distance, net distance, and speed of migration. Directionality (displacement/distance) was used as a measure of chemotaxis. A minimum of eight to 10 cells for each condition was examined from each of three separate experiments. Two to three cells from each quadrant were randomly selected prior to initiating tracking. Only cells that started and remained in the field of view over the entire course of video capture were analyzed. (A) Migratory tracks from one experiment where neutrophils were exposed to fMLP. "X" marks the position of the micropipette. (B) Migratory tracks from one experiment where neutrophils were exposed to fMLP together with Slit2. X marks the position of the micropipette. Panel inset depicts an enlarged view of the tracks made by a single neutrophil. (C) Graph depicting the mean migratory speed of resting neutrophils (Control), neutrophils exposed to fMLP alone, and neutrophils exposed to fMLP in conjunction with Slit2. Mean values Ϯ sem for three separate experiments. *, P Ͻ 0.01, versus Control. (D) Graph depicting the mean directionality of resting neutrophils (Control), neutrophils exposed to fMLP alone, and neutrophils exposed to fMLP together with Slit2. Mean values Ϯ sem for three separate experiments. *, P Ͻ 0.002, versus Control and versus fMLP ϩ Slit2.
Slit2 does not inhibit chemoattractant-induced activation of other major kinase pathways
We examined the effects of Slit2 on activation of a number of other kinase pathways associated with neutrophil chemotaxis, namely, PI3K, Akt, Erk, and p38 MAPK [49 -52] . As expected, stimulation of neutrophils with fMLP led to rapid phosphorylation of Akt, Erk, and p38-MAPK (Fig. 6, A-D; PϽ0.0005 for Akt; PϽ0.05 for Erk; PϽ0.05 for p-38 MAPK). Slit2 treatment had no effect on the basal level of kinase activation (Fig. 6 , A-D). Upon stimulation with fMLP, resulting levels of activated Akt were comparable in the presence or absence of Slit2, suggesting that Slit2 does not impair the ability of neutrophils to generate PIP 3 (Fig. 6, A and B) . Similarly, Slit2 treatment had no effect on fMLP-induced phosphorylation of Erk and p38 MAPK (Fig. 6, A, C, and D) . Collectively, these data suggest that Slit2 inhibits neutrophil chemotaxis by specifically preventing activation of Cdc42 and Rac2 but not activation of Akt, Erk, or p38 MAPK.
Slit2 inhibits leukocyte recruitment in peritoneal inflammation
To study the effects of Slit2 on neutrophil recruitment in vivo, we used a well-described mouse model of chemical irritant peritonitis [43] . In the presence of control medium, sodium periodate administration resulted in influx of 1.90 ϫ 10 6 Ϯ 0.50 ϫ 10 6 neutrophils (Fig. 7A) . When Slit2 was preadministered by i.p. injection, neutrophil recruitment to the peritoneal cavity decreased sixfold ( Fig. 7A; 0 .30ϫ10 6 Ϯ0.11ϫ10 6 ; PϽ0.05). When purified Slit2 was preadministered i.v. by tailvein injection, neutrophil influx fell from 0.86 ϫ 10 6 Ϯ 0.10 ϫ 10 6 to 0.05 ϫ 10 6 Ϯ 0.02 ϫ 10 6 ( Fig. 7B; PϽ0.001) . Although the number of other leukocyte subsets recruited to the peritoneal cavity was small, Slit2 also inhibited infiltration of several of them, especially monocytes/macrophages (Supplemental Table 1 ; PϽ0.01). Slit2 prevented neutrophil recruitment to the peritoneum in response to other chemoattractant factors, namely C5a and MIP-2 ( Fig. 7B ; C5a: 1.50ϫ10 6 Ϯ0.60ϫ10 6 ; C5aϩSlit2: 0.30ϫ10 6 Ϯ0.08ϫ10 6 ; PϽ0.001; MIP-2: 1.12ϫ10 6 Ϯ0.24ϫ10 6 ; MIP-2ϩSlit2: 0.65ϫ10 6 Ϯ0.19ϫ10 6 ; PϽ0.01). These data demonstrate that Slit2 acts as a potent inhibitor of chemotaxis for circulating neutrophils, as well as for other leukocytes, toward diverse inflammatory stimuli.
DISCUSSION
The aim of this study was to assess the effect of Slit2 on the migration of circulating neutrophils. We demonstrated that primary human neutrophils express Robo-1 and that exogenous application of Slit2 blocks migration of neutrophils in response to a chemotactic gradient. This observation is consistent with the effect of Slit2 on other cells expressing Robo-1 on their surface. Indeed, Slit2/Robo-1 have been shown recently to inhibit the migration of a number of different cell types, including cells of hematopoetic lineage such as dendritic cells and T lymphocytes [14 -16] . A major finding of our study is that Slit2 did not inhibit all movement but specifically, the directed migration of neutrophils. This is a particularly (C) Freshly isolated human and mouse neutrophils were incubated with Slit2 and plated on fibronectin-coated coverslips in a six-well tissue-culture plate. Cells were incubated with fMLP (1 M) for 3 min and then fixed, permeabilized with 0.1% Triton, and incubated with rhodamine-conjugated phalloidin for 30 min to visualize actin. Cells were examined using a Leica DMIRE2 spinning disc confocal microscope at ϫ100 magnification.
important distinction, as neutrophil chemotaxis to sites of injury is an important component of inflammatory tissue injury. Indeed, neutrophil-mediated tissue damage is associated with a number of inflammatory conditions, including rheumatoid arthritis and ischemia-reperfusion injury [2, 53] . The ability of Slit2 to disrupt neutrophil chemotaxis points specifically to the potential use of this agent as a novel therapeutic for inflammatory tissue injury. Although Slit2 has been shown to inhibit chemotactic migration of several cell types, the mechanisms that mediate these effects remain poorly understood. Neutrophil migration involves a complex series of events, in which the cell, upon sensing a chemotactic gradient, develops a polarized morphology with a wide lamella at the front and a narrow tail-like uropod at the back. Critical to the maintenance of this asymmetry and to forward propulsion is the rapid turnover of actin filaments at the lamella. In this study, we demonstrated that treatment of neutrophils with Slit2 led to a significant reduction in fMLP-stimulated generation of free barbed ends, which are required for rapid actin polymerization at the leading edge [37] . This observation is consistent with data from neuronal cells linking Robo-1 to proteins associated with the actin cytoskeleton, including Ena and srGAP1 [9, 10] . However, to the best of our knowledge, this study provides the first evidence linking Slit2 treatment directly to a reduction in chemoattractant-stimulated high-affinity actin filament ends.
In neutrophils undergoing chemotaxis, the family of small GTPases mediates turnover of actin. Indeed, treatment of cells with Clostridium difficile toxin, which inhibits GTPases by monoglucosylation, results in severe defects in actin turnover and migration [54] . Seminal work describing the effects of introducing dominant-negative cDNA constructs into HL-60 granolucytic cells identified Rac as the key determinant of actin assembly and Cdc42 as being responsible for maintaining the direction of migration [34] . Our studies and those of others demonstrate that Slit2 prevents activation of Cdc42 [10] . Accordingly, in HL-60 neutrophil-like cells, inhibition of Cdc42 using a dominant-negative allele prevents cells from moving up a chemotactic gradient efficiently and results in extension of random lamellae in all directions [34] .
We found that Slit2 also prevented chemoattractant-induced activation of Rac2. Similarly, Slit2 has been shown to suppress Rac activation in human vascular smooth muscle cells, human T lymphocytes, and murine RAW264.7 macrophages [13, 15, 16] . In murine neutrophils, Rac1 and Rac2 are expressed at similar levels, and each isoform has distinct functions. Neutrophils deficient in Rac1 display normal migratory velocity but reduced directionality toward chemotactic gradients [19] . In contrast, Rac2-deficient neutrophils demonstrate reduced migration speed but normal chemotactic migration [19] . Rac1deficient neutrophils show a partial reduction in chemoattractant-induced actin polymeraization, and the kinetics of actin assembly is delayed, preferentially inhibiting early rather than later events [43] . Overall, the effects of Slit2 that we observed on neutrophil migratory characteristics are highly reminiscent of Rac1 deficiency. In our experiments, rather than (C) Neutrophils were isolated from murine bone marrow as described in Materials and Methods. One million cells were suspended in 100 l Nucleofector TM solution (Amaxa, Inc.), supplemented with 6 g cDNA for PAK-PBD-YFP and H-Ras-RFP. Cells were transfected using a Cell Line V Nucleofector TM kit and the Nucleofector TM program Y-001. Transfected cells were recovered carefully with 500 l IMDM, prewarmed to 37°C, and transferred to 1.5 ml prewarmed IMDM, supplemented with 10% FBS in six-well plates for 2 h. After the recovery period, cells were incubated with purified Slit2 (4.5 g/ml) for 10 min. Cells were mounted on a 1% BSA-coated coverslip in an Attafluor cell chamber mounted on the 37°C heated stage of a Leica DMIRE2 inverted fluorescence microscope equipped with a Hamamatsu back-thinned EM-CCD camera and spinning disc confocal scan head. Cells were exposed to a point source of chemoattractant using a glass micropipette containing fMLP (1 M). Digital pictures were taken every 3 s for 5 min, and images were acquired and analyzed using Volocity™ software (Improvision). Images show the distribution of PAK-PBD-YFP, H-Ras-RFP, and the resulting YFP-RFP ratio at the leading edge compared with the trailing edge of cells exposed to fMLP alone or fMLP in the presence of Slit2. Arrows indicate the direction of the chemotactic gradient. Images are representative of at least 19 cells analyzed from three separate experiments. (D) Experiments were performed as described in C. Mean values Ϯ sem for the normalized MFI, calculated as the YFP:RFP ratio at the leading edge compared with the trailing edge of the cell. A minimum of 19 cells was analyzed from three separate experiments. *, P Ͻ 0.001. evaluate overall actin assembly, we focused on a key regulatory feature of this process, namely, generation of free high-affinity actin filament ends. Measurement of free barbed end formation determines specifically the initial burst of actin activity following chemotactic stimulation. Indeed, free barbed-end generation of actin is required for efficient cell chemotaxis. We found that Slit2 inhibited chemoattractant-induced generation of free barbed ends by over 50%. This falls in between values observed in Rac1-and Rac2-deficient neutrophils, in which a 30% defect and a 70% defect in free barbed end generation have been reported, respectively [21] . It is interesting to note that following chemotactic stimulation of Slit2-treated human neutrophils and Rac1-deficient murine neutrophils, random migration of cells remains intact, despite a partial defect in generation of actin high-affinity free barbed ends. Emerging data support the concept that the spatiotemporal dynamics of actin assembly within the migrating cell help to govern cell motility [55, 56] . In support of this notion is the recent discovery that hematopoietic protein 1 constitutes part of an organizational complex that localizes to propagating waves of actin nucleation within migrating neutrophils [55, 56] . These waves interact reciprocally with actin to define and organize the leading edge of neutrophils [56] . In this way, net cell movement results from the collective actions of multiple self-organizing actin-based waves.
At the molecular and cellular level, the effects of Slit2 on neutrophil migration share features akin to those seen in Rac1 and Rac2 null mice. This may be explained by the differences in expression of Rac isoforms between murine and human neutrophils. In murine neutrophils, Rac1 and Rac2 are expressed at equivalent concentrations. In human neutrophils, Rac2 expression is four to 40 times greater than that of Rac1 [47, 48, 57] . Thus, in human neutrophils, it is likely that Rac2 mediates functions assumed by Rac1 in murine neutrophils. In human neutrophils, it has proven difficult to delineate the individual functions of Rac1 and Rac2. The two GTPases are 92% homologous, and the guanine nucleotide exchange factors that regulate them are the same, rendering expression of mutant proteins in neutrophil-like cell lines an ineffective means of dissecting the individual roles played by Rac1 and Rac2 in chemotaxis. Moreover, human neutrophils are small, terminally differentiated cells, which are difficult to transfect, further complicating the ability to manipulate them experimentally. Together, our data suggest a mechanism of action, whereby Slit2 binding to Robo-1 in human neutrophils prevents chemoattractant-induced activation of Rac2 and Cdc42 with consequent disruption of actin free barbed end formation and ultimately, inhibition of directional neutrophil migration.
Stimulation of neutrophils by fMLP also leads to rapid phospholipid metabolism and activation of major kinase pathways, including Akt, Erk, and p38-MAPK, responsible for transcriptional changes. Studies using specific inhibitors demonstrate that disrupting each of these pathways disturbs neutrophil chemotaxis significantly. However, exogenous treatment with Slit2 had no effect on the chemoattractant-induced activation of any of the above pathways. We observed normal activation of the Akt pathway in response to chemotactic stimulation, suggesting that Slit2 does not inhibit phospholipid metabolism and specifically, generation of PIP 3 . These results were somewhat surprising, given the important role played by PIP 3 in chemotactic migration of neutrophils. In one study, neutrophils from PI3K␥-deficient mice displayed reduced directional migration toward chemotactic gradients [50] . Our data are, however, consistent with observations in human HL-60 granulocytic cells expressing a dominant-negative allele of Cdc42. In these studies, suppression of Cdc42 still led to normal PIP 3 production and Akt activation [34] . In yet another study, Slit2 prevented chemokine-induced activation of PI3K in human breast cancer cells [12] . We found further that in human neutrophils, Slit2 did not inhibit chemoattractant-induced activation of Erk, nor p38-MAPK. These data are in concordance with those of others, demonstrating that neither activation of p38-MAPK in Jurkat T lymphocytes nor activation of Erk in human granulocytic cells was affected by Slit2 [16, 17] . In another study, Slit2 prevented chemotaxis and chemoinvasion of breast cancer cells toward the chemokine CXCL12 and inhibited CXCL12-induced activation of Erk [12] . These differential effects of Slit2 on inducible kinase activity may be attributable to the different cell types used and to the different chemotactic agents used to stimulate them.
To determine whether Slit2 can prevent neutrophil recruitment in vivo, we used mouse models of peritoneal inflammation induced by local instillation of sodium periodate, C5a, or MIP-2. We found that administration of Slit2, i.p. or i.v., reduced neutrophil recruitment significantly. This is the first direct demonstration of potent anti-chemotactic actions of Slit2 on neutrophils in vivo. These data confirm a universal antimigratory role for Slit2 and are in keeping with recent work showing that Slit2 prevents pathologic neovascularization within the eye by inhibiting chemotaxis of endothelial cells toward vascular endothelial growth factor [18] . In another study, Slit2 ameliorated glomerulonephritis-associated kidney injury by inhibiting chemotactic infiltration of macrophages [15] . Our results would suggest that localized or systemic delivery of Slit2 may reduce neutrophil recruitment and subsequent tissue damage associated with inflammation. Soluble Slit2 is relatively "sticky" and could potentially be locally maintained at a high concentration by adhering to extracelleular matrix proteins such as glypican-1 [58] . Thus, after regional administration, Slit2 could be retained at sites of inflammation, such as joints and transplanted organs, thereby alleviating neutrophil-inflicted tissue injury associated with rheumatoid arthritis and ischemia reperfusion injury. As Slit2 blocks migration of several types of inflammatory cells, including neutrophils, T lymphocytes, macrophages, and dendritic cells, toward diverse chemotactic stimuli, it could act as a highly effective anti-inflammatory agent [14 -17] . Further studies are needed to explore the clinical use of Slit2 or a Slit-like agent for prevention and treatment of localized inflammation. 2 ml normal saline) by tail-vein injection. One hour later, mice were given 1 ml sodium periodate (5 mM), C5a (10 g), or MIP-2 (2.5 g) by i.p. injection. After 3 h, mice were killed and the peritoneal exudates collected by lavage with chilled PBS (5 ml/ mouse). Infiltrating leukocytes were counted using an electronic cell counter and the number of neutrophils quantified using Wright-Giemsa stain. Mean values Ϯ sem from four to six separate experiments per treatment condition. *, P Ͻ 0.001; **, P Ͻ 0.01.
